OSUGACESTAT - PharmaKB

OSUGACESTAT

Osugacestat is a small molecule pharmaceutical. It is currently being investigated in clinical studies.

Download report

Favorite

Events Timeline

Commercial

Clinical

Drug

Target

Variants

Financial

Trends

Safety

Events Timeline

YTD

Max

Events

FDA approval date

EMA approval date

Patent expiration date

Study first post date

Last update post date

Start date

Primary completion date

Completion date

Results first post date

Mock data
Subscribe for the real data

Commercial

No data

Clinical

Clinical Trials

11 clinical trials

View more details

Mock data
Subscribe for the real data

Indications Phases 4

No data

Indications Phases 3

No data

Indications Phases 2

Indication	MeSH	Ontology	ICD-10	Ph 1	Ph 2	Ph 3	Ph 4	Other	Total
Alzheimer disease	D000544	EFO_0000249	F03	—	2	—	—	—	2
Central nervous system diseases	D002493	—	G96.9	—	2	—	—	—	2
Brain diseases	D001927	—	G93.40	—	2	—	—	—	2
Nervous system diseases	D009422	—	G00-G99	—	2	—	—	—	2
Dementia	D003704	EFO_0003862	F03	—	2	—	—	—	2
Mental disorders	D001523	EFO_0000677	F91.9	—	2	—	—	—	2

Indications Phases 1

No data

Indications Without Phase

No data

Epidemiology

Epidemiological information for investigational and approved indications

View more details

Drug

General

Drug common name	OSUGACESTAT
INN	osugacestat
Description	(2S,3R)-N'-[(3S)-1-methyl-2-oxo-5-phenyl-3H-1,4-benzodiazepin-3-yl]-2,3-bis(3,3,3-trifluoropropyl)butanediamide is a primary carboxamide, a secondary carboxamide and a tertiary carboxamide.
Classification	Small molecule
Drug class	enzyme inhibitors: gamma secretase inhibitors
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)	CN1C(=O)[C@@H](NC(=O)[C@H](CCC(F)(F)F)[C@H](CCC(F)(F)F)C(N)=O)N=C(c2ccccc2)c2ccccc21